Veterinary/Animal Vaccines Market Size & Forecast Report, 2014 - 2025

The Global Veterinary/Animal Vaccines Market is expected to reach USD 12.6 billion by 2025. Vaccine administration is a process that increases the resistance or immune power to an infectious disease. Veterinary/animal vaccines aim to recover the welfare and health of companion animals, prevent the transmission of diseases from animals to humans from wildlife as well as domestic animals, and cost-efficiently rise the production of livestock. The vaccines may be administered via oral or parenteral routes. The Veterinary Vaccines Market is estimated to grow at a significant CAGR over the forecast period as the scope and its applications are rising enormously across the globe.

Growing livestock population, rise in breakouts of livestock diseases, increasing zoonotic diseases, increasing initiative by government agencies, and growing number of key players are documented as major factors of Veterinary/Animal Vaccines industry that are estimated to enhance the growth in the years to come. However, the high cost of vaccines and their storage is the factor that may restrain overall market growth in the coming years. Animal Vaccines Market is segmented based on type, disease type, technology, and region.

Aquaculture Vaccines, Porcine Vaccines, Companion Animal Vaccines, Poultry Vaccines, Livestock Vaccines, and other types could be explored in Veterinary/Animal Vaccines in the forecast period. Livestock vaccines include Small Ruminant Vaccines and Bovine Vaccines. On the other hand, companion animal vaccines include Feline Vaccines and Canine Vaccines.

The porcine vaccines sector accounted for the largest market share of Veterinary/Animal Vaccines in terms of value. In addition, the Companion Animal Vaccines sector is estimated to grow at the fastest pace in the coming years. This may be because of growing awareness regarding companion animal vaccination, increasing number of pet and pet ownership, and growing occurrence of zoonotic diseases in humans.

Aquaculture Diseases, Porcine Diseases, Companion Animal Diseases, Poultry Diseases, Livestock Diseases, and others are the diseases that could be explored in Veterinary/Animal Vaccines in the forecast period. The porcine sector accounted for a substantial market share and is estimated to lead the overall market in the coming years.

The enhanced technology includes Recombinant Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Inactivated Vaccines, and others that could be explored in the forecast period. The live attenuated vaccines sector accounted for the substantial market share of Veterinary/Animal Vaccines and is estimated to continue its dominance in the coming years. This may be because it offers long-term immunity and can be administered easily.

Globally, Europe is accounted for the substantial market share of Veterinary/Animal Vaccines in terms of revenue and is estimated to lead the overall market in the coming years. The reason behind the overall market growth could be the rising use of enhanced technology and the presence of key manufacturers in the region. Instead, North America and the Asia Pacific are also estimated to have a positive influence on future growth.

North America is the second-largest region with a significant market share. However, Asia Pacific is estimated to grow at the fastest pace with the highest CAGR in the foremost period. The aspects that may be ascribed to the growth comprise growing investment in vaccine manufacturing services in developing countries, growing pet adoption, and the development of key manufacturers in the region.

The key players of the Veterinary/Animal Vaccines Market are Virbac, Zoetis, Phibro Animal Health, Merck Animal Health, Ceva, Elanco, and Boehringer Ingelheim. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As companies all over the world have to believe that alliance with a market would permit them proportional market existence and authority to declare the leadership position.

Market Segment:

Product Outlook (Revenue, USD Million, 2014 - 2025)
    • Attenuated Live Vaccines
    • Inactivated Vaccines
    • Subunit Vaccines
    • DNA Vaccines
    • Recombinant Vaccines

Animal Type Outlook (Revenue, USD Million, 2014 - 2025)
    • Companion Animal Vaccines.
        • Canine
            • Distemper
            • Kennel cough (Parainfluenza)
            • Parvovirus
            • Canine herpes
            • Lyme Disease
        • Feline
            • Feline calicivirus
            • Peritonitis (FIP)
            • Feline FIV
    • Cattle Vaccines
        • BRSV
        • Enzootic Bronchopneu
        • IBR
        • BVD/MD
    • Poultry Vaccines
        • Bronchitis
        • Avian Influenza
        • Marek's Disease
        • Newcastle Disease
    • Pig Vaccines
        • Porcine reproductive disease
        • Swine Influenza
        • Swine Pneumonia
    • Equine Vaccines
        • Encephalomyelitis
        • Rhinopneumonitis
        • Influenza (Horse Flu)

Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America
        • the U.S.
        • Canada
    • Europe
        • the U.K.
        • Germany
    • the Asia Pacific
        • India
        • China
    • Latin America
        • Brazil
        • Mexico
    • Middle East & Africa
        • South Africa